Michael Millenson

8.9k total citations · 2 hit papers
64 papers, 4.5k citations indexed

About

Michael Millenson is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Millenson has authored 64 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 38 papers in Pathology and Forensic Medicine and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Millenson's work include Lymphoma Diagnosis and Treatment (38 papers), Viral-associated cancers and disorders (17 papers) and Lung Cancer Treatments and Mutations (16 papers). Michael Millenson is often cited by papers focused on Lymphoma Diagnosis and Treatment (38 papers), Viral-associated cancers and disorders (17 papers) and Lung Cancer Treatments and Mutations (16 papers). Michael Millenson collaborates with scholars based in United States, Italy and Canada. Michael Millenson's co-authors include Scott J. Rodig, Li Zhu, Philippe Armand, Ahmad Halwani, Deepika Cattry, Emma C. Scott, Margaret A. Shipp, Ivan Borrello, Alexander M. Lesokhin and Joseph F. Grosso and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Millenson

64 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

2014 2.7k citations Stephen M. Ansell, Alexander M. Lesokhin et al. New England Journal of Medicine profile →
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

2013 609 citations Zheng Zhou, Alfred Rademaker et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Millenson United States	22	3.0k	2.0k	1.4k	747	632	64	4.5k
Dok Hyun Yoon South Korea	35	2.4k 0.8×	2.1k 1.1×	721 0.5×	572 0.8×	785 1.2×	303	4.3k
Martin Gutierrez United States	15	3.0k 1.0×	1.2k 0.6×	1.5k 1.1×	480 0.6×	500 0.8×	44	4.0k
John Sweetenham United States	34	2.0k 0.7×	2.8k 1.4×	785 0.6×	1.5k 2.0×	468 0.7×	143	4.6k
William R. Macon United States	39	2.4k 0.8×	3.6k 1.8×	921 0.7×	1.3k 1.7×	269 0.4×	139	4.9k
Paul A. Hamlin United States	33	2.0k 0.7×	2.9k 1.4×	587 0.4×	925 1.2×	521 0.8×	155	4.0k
Ahmad Halwani United States	15	2.3k 0.8×	1.1k 0.6×	1.4k 1.0×	453 0.6×	392 0.6×	68	3.3k
Bernd Metzner Germany	36	2.9k 1.0×	3.4k 1.7×	682 0.5×	1.6k 2.1×	1.2k 2.0×	126	5.6k
Kieron Dunleavy United States	36	2.7k 0.9×	3.6k 1.8×	827 0.6×	1.6k 2.2×	456 0.7×	149	5.6k
Michael Unterhalt Germany	33	3.0k 1.0×	4.0k 2.0×	490 0.3×	2.0k 2.7×	732 1.2×	166	5.0k
Karim Belhadj France	25	1.6k 0.5×	2.3k 1.2×	444 0.3×	779 1.0×	468 0.7×	101	3.6k

Countries citing papers authored by Michael Millenson

Since Specialization

Citations

This map shows the geographic impact of Michael Millenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Millenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Millenson more than expected).

Fields of papers citing papers by Michael Millenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Millenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Millenson. The network helps show where Michael Millenson may publish in the future.

Co-authorship network of co-authors of Michael Millenson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Millenson. A scholar is included among the top collaborators of Michael Millenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Millenson. Michael Millenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilde, Lindsay, Adam Binder, Matthew Carabasi, et al.. (2020). COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience. Blood. 136(Supplement 1). 36–37. 1 indexed citations

Herrera, Alex F., Allison Crosby‐Thompson, Jonathan W. Friedberg, et al.. (2014). Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network. Cancer. 120(13). 1993–1999. 27 indexed citations

Zhou, Zheng, Alfred Rademaker, Leo I. Gordon, et al.. (2014). High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender. Blood. 124(21). 3046–3046. 1 indexed citations

Rodgers, George M., Jeffrey A. Gilreath, Morey A. Blinder, et al.. (2014). NCCN Guidelines Version 3.2014 Panel Members Cancer- and Chemotherapy-Induced Anemia. 3 indexed citations

Ansell, Stephen M., Alexander M. Lesokhin, Ivan Borrello, et al.. (2014). PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. New England Journal of Medicine. 372(4). 311–319. 2663 indexed citations breakdown →

Abou-Nassar, Karim, Ann Vanderplas, Jonathan W. Friedberg, et al.. (2013). Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leukemia & lymphoma. 54(10). 2155–2162. 9 indexed citations

Rodgers, George M., Pamela S. Becker, Morey A. Blinder, et al.. (2012). Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network. 10(5). 628–653. 171 indexed citations

Millenson, Michael, Nasser H. Hanna, Corey J. Langer, et al.. (2010). Pemetrexed (Pem) plus gemcitabine (Gem) or carboplatin (Carbo) in patients (pts) with advanced malignant mesothelioma (MPM): A randomized phase II trial, E1B03.. Journal of Clinical Oncology. 28(15_suppl). e18053–e18053. 1 indexed citations

Al‐Saleem, Tahseen, et al.. (2009). Pediatric nodal marginal zone lymphoma may develop in the adult population. Leukemia & lymphoma. 51(1). 89–94. 11 indexed citations

10.

Feigenberg, Steven J., Alexandra L. Hanlon, Corey J. Langer, et al.. (2007). A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(4). 287–292. 31 indexed citations

11.

Langer, Corey J., Robert A. Somer, Samuel Litwin, et al.. (2007). Phase I Study of Radical Thoracic Radiation, Weekly Irinotecan, and Cisplatin in Locally Advanced Non-small Cell Lung Carcinoma. Journal of Thoracic Oncology. 2(3). 203–209. 7 indexed citations

12.

Langer, Corey J., Karen Ruth, Hossein Borghaei, et al.. (2007). PD3-2-8: Phase II Trial of Cetuximab (C225) in Combination with Monthly Carboplatin (Cb) and Weekly Paclitaxel (Pac) in Patients with Advanced NSCLC: Promising Early Results. Journal of Thoracic Oncology. 2(8). S465–S466. 1 indexed citations

13.

Al‐Saleem, Tahseen, et al.. (2006). Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 47(9). 1902–1907. 17 indexed citations

14.

Roberts, John D., Mitchell R. Smith, Eric J. Feldman, et al.. (2006). Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clinical Cancer Research. 12(19). 5809–5816. 33 indexed citations

15.

Borghaei, Hossein, Mitchell R. Smith, Michael Millenson, et al.. (2006). Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma.. Blood. 108(11). 4710–4710. 1 indexed citations

16.

Borghaei, Hossein, Michael Millenson, Russell J. Schilder, et al.. (2004). Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non‐Hodgkin lymphoma. Cancer. 101(9). 2034–2041. 3 indexed citations

17.

Wu, Hong, Mitchell R. Smith, Michael Millenson, et al.. (2003). Contribution of Flow Cytometry in the Diagnosis of Cutaneous Lymphoid Lesions. Journal of Investigative Dermatology. 121(6). 1522–1530. 17 indexed citations

18.

Adonizio, Christian S., James S. Babb, Chao Huang, et al.. (2002). Temozolomide in Non—Small-Cell Lung Cancer: Preliminary Results of a Phase II Trial in Previously Treated Patients. Clinical Lung Cancer. 3(4). 254–258. 32 indexed citations

19.

Schilder, Russell J., Melvyn Goldberg, Michael Millenson, et al.. (2000). Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung. Lung Cancer. 27(1). 37–45. 10 indexed citations

20.

Langer, Corey J., Michael Millenson, Peter J. O’Dwyer, et al.. (1996). Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.. PubMed. 23(6 Suppl 16). 35–41. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact